GlassScriptPhysician profile
Sadaf Noor
NPI 1194108555
$4,928.07
in general payments reported to CMS, 2019-2025
27 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $53.38 · 2021: $735 · 2022: $259 · 2023: $546 · 2024: $1,491 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,880.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,250.03 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $705.11 | 2021-2025 | Rexulti |
| Lundbeck LLC | $405.78 | 2020-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $358.20 | 2021-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $326.06 | 2021-2025 | Trintellix |
| Corium, LLC | $225.00 | 2023-2025 | Azstarys |
| Tris Pharma INC | $210.65 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Axsome Therapeutics, INC. | $176.03 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $165.77 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $148.98 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.26 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $105.65 | 2021-2025 | Wellbutrin, Aplenzin |
| Neurocrine Biosciences, INC. | $87.07 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $82.41 | 2021-2024 | Austedo Xr |
| Neos Therapeutics, LP | $76.30 | 2020-2025 | Adzenys Xr-Odt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $65.06 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $58.54 | 2022 | |
| Neuronetics, INC. | $58.31 | 2022 | |
| Collegium Pharmaceutical, INC. | $54.91 | 2025 | Jornay Pm |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.36 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $35.32 | 2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $34.96 | 2021 | |
| Alkermes, INC. | $31.36 | 2021-2025 | Vivitrol |
| Noven Therapeutics, LLC | $22.93 | 2023 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $22.05 | 2024 | |
| Eisai INC. | $20.53 | 2021 | |
| Almatica Pharma LLC | $16.44 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadaf Noor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.